Question explored with the scientific record
Conversation so far
- 1 Do statins reduce strokes?
- 2 What benefits do statins show for people without heart disease (primary prevention)?
- 3 What about ezitimibe for cardiovascular disease and stroke prevention
Answered on this page ↓
What about ezitimibe for cardiovascular disease and stroke prevention
Ezetimibe added to a statin reduces cardiovascular events in people with established disease, but the effect is small, the trial evidence is thin on stroke specifically, and the benefit vanishes for mortality.
The single biggest trial, IMPROVE-IT, followed 18,144 patients after a heart attack for about 6 years. Adding ezetimibe to simvastatin reduced the combined endpoint of cardiovascular death, heart attack, stroke, and revascularization by 6% relative—an absolute drop of about 2 events per 100 people [2][4]. That is a number needed to treat of about 50 to prevent one first event. The trial was funded by Merck, the manufacturer.
For stroke specifically, the same meta-analysis of nine trials found a 23% relative reduction in ischemic stroke (odds ratio 0.77), but no reduction in all-cause death (OR 0.94, confidence interval crossing 1.0) [3]. A 2024 Korean real-world study found moderate statin plus ezetimibe was associated with 17% fewer strokes than high-intensity statin alone (HR 0.83), but that is observational data, not a randomized trial [5].
| Outcome | Ezetimibe added to statin | Statin alone |
|---|---|---|
| First cardiovascular event (6 yr) | ~32% | ~34% [4] |
| Ischemic stroke risk (meta) | 23% relative reduction | — [3] |
| All-cause death (meta) | No significant difference | — [3] |
The SEAS trial in aortic stenosis raised a cancer signal: 11.1% of the ezetimibe/simvastatin group developed cancer vs 7.5% on placebo [1]. That was not replicated in larger trials, but it has never been cleanly ruled out.
My call: ezetimibe likely reduces heart attacks and strokes when added to a statin in people who already have heart disease, with no clear effect on whether you live longer. For someone without established disease, the benefit is far smaller and the safety questions are unresolved. Confidence: moderate.
Sources used 5
-
At Sea with SEAS: The First Clinical Endpoint Trial for Ezetimibe, Treatment of Patients with Mild to Moderate Aortic Stenosis, Ends with Mixed Results and More Controversy
The SEAS trial investigated the effects of simvastatin and ezetimibe on cardiovascular events and aortic valve replacement in patients with mild to moderate aortic stenosis, finding a significant reduction in cardiovascular events but no impact on aortic valve progression or sur…
DOI: 10.1016/j.hlc.2009.02.007 -
Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes
In people with diabetes, fibrates and niacin did not reduce cardiovascular events, whereas ezetimibe, evolocumab, and alirocumab reduced non-fatal cardiovascular events when added to statins.
DOI: 10.15277/bjd.2018.180 -
P5015Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events: A meta-analysis
In a meta-analysis of 9 randomized controlled trials including 100,610 patients, intensified lipid-lowering therapy with ezetimibe or PCSK9 inhibitors added to statins reduced cardiovascular events by 18%, myocardial infarction by 16%, and ischemic stroke by 23%, but did not sig…
DOI: 10.1093/eurheartj/ehz746.0193 -
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
In the IMPROVE-IT trial, adding ezetimibe to simvastatin after acute coronary syndrome reduced not only first cardiovascular events but total cardiovascular events over a median follow-up of about 6 years, driven primarily by fewer myocardial infarctions and ischemic strokes, su…
DOI: 10.1016/j.jacc.2015.10.077 -
Comparative effectiveness of moderate-intensity statin with ezetimibe therapy versus high-intensity statin monotherapy in patients with acute coronary syndrome: a nationwide cohort study
In this nationwide propensity-matched cohort of Korean patients with acute coronary syndrome after percutaneous coronary intervention, moderate-intensity statin with ezetimibe was associated with lower risk of the composite of myocardial infarction, stroke, and all-cause mortali…
DOI: 10.1038/s41598-024-51310-5